Helix Acquisition (HLXB)

Overall impact
D (38)

Commentary

Helix Acquisition is a below-average overall performer. With a 'D' rating of 38.2 for overall impact (bottom 25% of all companies), Helix Acquisition ranks 201st out of 217 industry peers, behind United Clinics, Allied Physicians Group, Southern Veterinary Partners and 197 others, and ahead of Air Methods, Rock Dental Brands, Waystar Holding Corp and 13 others. On top material causes for Helix Acquisition's industry (Commercial Services & Supplies), Helix Acquisition performs well in Child and Maternal Health (95.2 score), Child and Maternal Health (95.2), Child and Maternal Health (95.2) and 3 other causes where it received an 'A' score and performs poorly in Technology Innovation (32.9 score), Disaster Readiness and Effective Aid (15.9), Technology Innovation (32.9) and 34 other causes where it received a 'D' or 'F' score.
Impact
Cause HLXB
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2020
Sector
Health Care
Industry
Health Care Providers & Services
Sub-industry
Health Care Services
SASB industry
Professional & Commercial Services
Headquarters
Massachusetts, United States
Share classes
HLXB
Description
Helix Acquisition Corp. focuses on acquiring companies primarily in the healthcare and healthcare-related industries. The company successfully completed its initial public offering (IPO) and raised approximately $115 million. The primary target for acquisition was MoonLake Immunotherapeutics AG, with a deal size of around $360 million, announced on October 4, 2021, and closed on April 5, 2022.
Material causes
Ethos considers the following causes material for Helix Acquisition, based on its industry sub-industry Health Care Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.